UnfoldIPThemes

Company patents

CAAMTECH, INC.

CAAMTECH, INC's patent strategy is heavily concentrated in pharmaceutical chemistry, with Heterocyclic Compounds representing 82.4% of its portfolio and Pharmaceutical Preparations at 67.6%. While these core areas saw significant growth in 2024 (Heterocyclic Compounds +140.0%, Pharmaceutical Preparations +54.5%), the company appears to be shifting its focus, as evidenced by a substantial decline in patenting activity across all categories so far in 2026, including a 77.3% drop in Heterocyclic Compounds and a 70.6% drop in Pharmaceutical Preparations compared to 2025.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

74 US filings (since 2023) · 5 categories · 5 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)Pharmaceutical PreparationsAcyclic / Carbocyclic Compounds
Who else files here? →
29since 2023
-38.5%YoY
API Solid Form Engineering

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
21since 2023
+83.3%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
20since 2023
+14.3%YoY
Drug Candidate Synthesisfiltered

Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.

General Organic Chemistry Methods
Who else files here? →
18since 2023
+66.7%YoY
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
2since 2023
new

Patents

Showing 1-10 of 20

Drug Candidate Synthesis
Page 1 of 2
US 20260116851 A1APPLICATION
C07C321/28

2-(2,5-DIETHOXY-4-(ETHYLTHIO)PHENYL)ETHANE-1-AMINIUM CHLORIDE

Filed:2024-02-15Pub:2026-04-30
Applicant:CAAMTECH, INC.

The disclosure relates to 2-[2.5-diethoxy-4-(ethylsulfanyl)phenyl]ethan-1-aminium chloride (2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride), crystalline 2-(2,5-diethoxy-4-(ethylthio)phenyl) ethane-1-aminium chloride, and specific crystalline forms thereof, including crystalline form 1 of 2-(2,5-diethoxy-4-(ethylthio)phenyl) ethane-1-aminium chloride, to compositions containing the same, and to methods of treatment using them.

US 20250361206 A1APPLICATION
C07D209/16

4-PIVALOYLOXY-N-METHYLTRYPTAMMONIUM CHLORIDE

Filed:2023-06-07Pub:2025-11-27
Applicant:CAAMTECH, INC.

The disclosure relates to (2-{4-[(2,2-dimethylpropanoyl)oxy]-1H-indol-3-yl}ethyl)(methyl)azanium chloride (4-pivaloyloxy-N-methyltryptammonium chloride), crystalline 4-pivaloyloxy-N-methyltryptammonium chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-pivaloyloxy-N-methyltryptammonium chloride, to compositions containing the same, and to methods of treatment using them.

US 20250282719 A1APPLICATION
C07C323/32

2-(2-ETHOXY-4-(ETHYLTHIO)-5-METHOXYPHENYL)ETHAN-1-AMINIUM CHLORIDE

Filed:2023-09-25Pub:2025-09-11
Applicant:CAAMTECH, INC.

The disclosure relates to 2-[2-ethoxy-4-(ethylsulfanyl)-5-methoxy phenyl]ethan-1-aminium chloride (2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl) ethan-1-aminium chloride), crystalline 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl) ethan-1-aminium chloride, and specific crystalline forms thereof, including crystalline form 1 of 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl) ethan-1-aminium chloride, to compositions containing the same, and to methods of treatment using it.

US 20250281458 A1APPLICATION
A61K31/4045

DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USES

Filed:2025-05-23Pub:2025-09-11
Applicant:CAAMTECH, INC.

The disclosure relates to a compound of formula (I): The disclosure also relates compound of formula (Ia): The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

US 12391645 B2GRANTED
C07D209/16

N-isopropyl tryptamines and method of making monoalkylated and dialkylated tryptamine analogs

Filed:2023-05-22Pub:2025-08-19
Applicant:CAAMTECH, INC.

The disclosure relates to [2-(5-chloro-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-chloro-N isopropyltryptammonium iodide or 5-Cl-NiPT iodide), crystalline 5-Cl-NiPT iodide, [2-(5-methoxy-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-methoxy-N-isopropyltryptammonium iodide or 5-MeO-NiPT iodide), crystalline 5-MeO-NiPT iodide, [2-(5-methyl-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-methyl-N-isopropyltryptammonium iodide or 5-Me-NiPT iodide), crystalline 5-Me-NiPT iodide, [2-(2-methyl-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (2-methyl-N-isopropyltryptammonium iodide or 2-Me-NiPT iodide), crystalline 2-Me-NiPT iodide, [2-(7-methyl 1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (7-methyl-N-isopropyltryptammonium iodide or 7-Me-NiPT iodide), crystalline 7-Me-NiPT iodide, [2-(5-fluoro-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-fluoro-N-isopropyltryptammonium iodide or 5-F-NiPT iodide), crystalline 5-F-NiPT iodide, and specific crystalline forms thereof, including crystalline form 1 of 5-Cl-NiPT iodide, crystalline form 1 of 5-MeO-NiPT iodide, crystalline form 1 of 5-Me-NiPT iodide, crystalline form 1 of 2-Me-NiPT iodide, crystalline form 1 of 7-Me-NiPT iodide, and crystalline form 1 of 5-F-NiPT iodide, to compositions containing the same, and to methods of treatment using them. This disclosure relates to monoalkylated and dialkyled tryptamine analogs, and to methods of treatment/therapeutic uses thereof. This disclosure relates to an improved method of making monoalkylated and dialkylated tryptamine analogs.

US 12343328 B2GRANTED
A61K31/4045

Dialkyl tryptamines and their therapeutic uses

Filed:2021-12-08Pub:2025-07-01
Applicant:CAAMTECH, INC.

The disclosure relates to a compound of formula (I): The disclosure also relates to a compound of formula (Ia): The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

US 20250197352 A1APPLICATION
C07D209/16

N-ISOPROPYL TRYPTAMINES AND METHOD OF MAKING MONOALKYLATED AND DIALKYLATED TRYPTAMINE ANALOGS

Filed:2023-05-22Pub:2025-06-19
Applicant:CAAMTECH, INC.

The disclosure relates to [2-5-chloro-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-chloro-N isopropyltryptammonium iodide or 5-Cl-NiPT iodide), crystalline 5-Cl-NiPT iodide, [2-(5-methoxy-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-methoxy-N-isopropyltryptammonium iodide or 5-MeO-NiPT iodide), crystalline 5-MeO-NiPT iodide, [2-(5-methyl-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-methyl-N-isopropyltryptammonium iodide or 5-Me-NiPT iodide), crystalline 5-Me-NiPT iodide, [2-(2-methyl-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (2-methyl-N-isopropyltryptammonium iodide or 2-Me-NiPT iodide), crystalline 2-Me-NiPT iodide, [2-(7-methyl 1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (7-methyl-N-isopropyl-tryptammonium iodide or 7-Me-NiPT iodide), crystalline 7-Me-NiPT iodide, [2-(5-fluoro-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-fluoro-N-isopropyltryptammonium iodide or 5-F-NiPT iodide), crystalline 5-F-NiPT iodide, and specific crystalline forms thereof, including crystalline form 1 of 5-Cl-NiPT iodide, crystalline form 1 of 5-MeO-NiPT iodide, crystalline form 1 of 5-Me-NiPT iodide, crystalline form 1 of 2-Me-NiPT iodide, crystalline form 1 of 7-Me-NiPT iodide, and crystalline form 1 of 5-F-NiPT iodide, to compositions containing the same, and to methods of treatment using them. This disclosure relates to monoalkylated and dialkyled tryptamine analogs, and to methods of treatment/therapeutic uses thereof. This disclosure relates to an improved method of making monoalkylated and dialkylated tryptamine analogs.

US 20250171456 A1APPLICATION
C07D487/14

PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES

Filed:2023-02-01Pub:2025-05-29
Applicant:CAAMTECH, INC.

The disclosure relates to compounds of formulae (I), (II), (III), and (IV): The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formulae (I), (II), (III), or (IV) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formulae (I), (II), (III), or (IV) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formulae (I), (II), (III), or (IV).

US 20250162991 A1APPLICATION
C07D209/16

CRYSTALLINE 5-METHOXY-DIPROPYL TRYPTAMINE COMPOUNDS

Filed:2024-09-27Pub:2025-05-22
Applicant:CAAMTECH, INC.

The disclosure relates to crystalline form 1 of [2-(5-methoxy-1H-indol-3-yl)ethyl]dipropylamine (5-MeO-DPT) and to crystalline form 1 of bis([2-(5-methoxy-1H-indol-3-yl)ethyl]dipropylazanium) (2E)-but-2-enedioate (5-MeO-DPT fumarate), and to pharmaceutical compositions containing the compounds and methods of treatment using them.

US 20250129022 A1APPLICATION
C07D209/16

TRYPTAMINE DERIVATIVES

Filed:2023-04-13Pub:2025-04-24
Applicant:CAAMTECH, INC.

The disclosure relates to (2-{4-[(methoxycarbonyl)oxy]-1H-indol-3-yl}ethyl)bis(propan-2-yl)azanium chloride (4-methylcarbonato-N,N-diisopropyltryptramine chloride or 4-methylcarbonato-DiPT chloride), crystalline 4-methylcarbonato-DiPT chloride, [2-(1H-indol-3-yl)ethyl](propan-2-yl)amine (N-isopropyltryptamine or NiPT), crystalline NiPT, N-[2-(1H-indol-3-yl)ethyl]propan-2-amine hydrobromide (N-isopropyltryptamine hydrobromide or NiPT hydrobromide), crystalline NiPT hydrobromide, N-[2-(1H-indol-3-yl)ethyl]cyclohexanamine (N-cyclohexyltryptamine), crystalline N-cyclohexyltryptamine, 2-(1H-in-dol-3-yl)ethanamine (tryptamine), crystalline tryptamine, N-[2-(1H-indol-3-yl)ethyl]cyclohexanamine hydrobromide (N-cyclohexyltryptamine hydrobromide), crystalline N-cyclohexyltryptamine hydrobromide, and specific crystalline forms thereof, including crystalline form 1 of 4-methylcarbonrato-DiPT chloride, crystalline form 1 of NiPT, crystalline form 1 of NiPT hydrobromide, crystalline form 1 of N-cyclohexyltryptamine, crystalline form 1 of tryptamine, and crystalline form 1 of N-cyclohexyltryptamine hydrobromide, to compositions containing the same, and to methods of treatment using them.

12